Biomerica

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, North America, Asia, South America, and Middle East. The company was founded in September 1971 and is headquartered in Irvine, CA.

NEWPORT BEACH, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, announced a significant advance in the management of irritable bowel syndrome (IBS). The inFoods® IBS diagnostic test has now been validated for use with finger stick (capillary) patient whole blood samples simplifying sample collection and facilitating wider access to the test.  With this new finger stick blood collection option, any trained medical professional in the doctor's office can collect the patient's blood sample during their office visit and forward the sample to the Lab for processing. This workflow enhancement greatly simplifies the process for healthcare providers to order the inFoods IBS test and is much easier for patients.  The InFoods IBS test will continue to be available using blood collected from a patient's arm (venipuncture) by a trained phlebotomist.

inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology

IRVINE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic products, is pleased to announce that inFoods® IBS, a revolutionary new approach to alleviate Irritable Bowel Syndrome (IBS) symptoms, is now available at the flagship office of Gastro Health in Miami, with plans expand into the other Gastro Health offices in the future.

Biomerica's inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).

IRVINE, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced its fiscal third quarter and nine month results ended February 28, 2023.

Biomerica Reports Q3 Fiscal 2023 Results

IRVINE, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced the launch of its InFoods® IBS test. The test is being performed in a CLIA-certified, and CAP accredited high-complexity laboratory facility and offered as a laboratory developed test (LDT). The Company further announced all validation testing necessary for the InFoods IBS product to be offered as an LDT has been completed. The first patient samples have been processed.

Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed

IRVINE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today the closing of its previously announced underwritten public offering of an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per share for total gross proceeds of $8 million, before deducting underwriting discounts and commissions and other offering-related expenses payable by Biomerica. All of the shares of common stock sold in the offering were offered by Biomerica.

Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock

IRVINE, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today the pricing of its previously announced underwritten public offering. Biomerica is offering an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per share. All shares of common stock in the offering are being offered by Biomerica.

Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock

IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today that it has commenced an underwritten public offering of its common stock. All shares of common stock in the proposed offering are being offered by Biomerica. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Biomerica Announces Proposed Underwritten Public Offering of Common Stock

IRVINE, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- IRVINE, CABiomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its second quarter fiscal 2023 financial results for the period ended November 30, 2022.

Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board which is advising the Company on the commercialization of products based on the Biomerica InFoods® Technology platform, beginning with the InFoods® IBS product. InFoods® IBS is the first of its kind diagnostic guided therapy using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of Irritable Bowel Syndrome (IBS) without the use of drugs.

Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company's Scientific Advisory Board

Expands Commercialization Efforts in Areas with High Unmet Needs Expands Commercialization Efforts in Areas with High Unmet Needs

Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE

IRVINE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) announced that data derived from a clinical study of InFoods® IBS was presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting in a poster titled “IgG-based Elimination Diets for Patients with IBS: Results From a Prospective, Multi-Center, Double-Blind, Placebo-Controlled Trial.” The poster was selected by ACG as a “Presidential Poster.” Fewer than 5% of accepted ACG abstracts each year receive this distinction, which is awarded for high quality, novel and potentially industry disruptive research.

Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting

Like a turbulent airplane ride, Biomerica (NASDAQ: BMRA ) suffered a seesaw over recent sessions. Initially, BMRA stock skyrocketed on Friday morning on news that Walmart (NYSE: WMT ) will sell the underlying company's breast self-exam device.

Biomerica (BMRA) Stock Gets Boost From Walmart Sales Expansion

Shares of Biomerica Inc. BMRA, +7.58% shot up 13.1% toward a 6-month high in active morning trading Friday, after the medical diagnostic products company said Walmart Inc. WMT, +0.45% will start selling its Aware Breast Self Exam device in about half its stores. Trading volume ballooned to 1.8 million shares, compared with the full-day average of about 57,200 shares.

Biomerica stock leaps as Walmart expands sales of Aware Breast Self Exam to its stores

IRVINE, Calif., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that under a General Merchandise Supplier Agreement with Walmart, the Company's Aware® Breast Self Exam device will now be sold in over 2400 Walmart's retail stores. In July, the Company announced that Walmart had begun selling the Aware product online through Walmart.com. Walmart has now determined to also sell Aware in-store, at approximately 50% of their retail store locations. Biomerica has received and shipped an Initial stocking order from Walmart, and the product should be on store shelves within weeks. The product retails for $19.95.

Walmart to Expand Sales of Biomerica's Aware® Breast Self Exam; Product will now be available in over 2400 Walmart stores

IRVINE, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the three months ended August 31, 2022 of $1.67 million, versus net sales of $1.26 million for the same period in the previous year, a 30% increase.

Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022

IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced plans to launch its InFoods® IBS test before calendar year end. The test will be performed in a CLIA-certified, high-complexity laboratory facility and offered as a laboratory developed test (LDT). The Company further announced it has hired Robert Carlson to serve as the Company's Chief Commercial Officer in preparation for the launch of InFoods IBS.

Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer

IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2022 financial results.

Biomerica Reports Fiscal 2022 Year End Results

Biomerica Inc (NASDAQ: BMRA) announced that its Aware Breast Self Exam device will now be sold in Walmart Inc's (NYSE: WMT) retail system.  The Biomerica FDA-cleared Aware Breast Self Exam device is a way for women to enhance tactile sensitivity to changes or.

Walmart to Start Selling Biomerica's Aware Breast Self Exam Devices

IRVINE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that under a General Merchandise Supplier Agreement with Walmart, the Company's Aware ® Breast Self Exam device will now be sold in Walmart's retail system. Biomerica has now shipped its first orders of the Aware ® product to Walmart, and Walmart will initially begin selling the product through its online sales channel in the USA ( https://www.walmart.com/ip/seort/395477102 ).

Walmart to Begin Selling Biomerica's Aware® Breast Self Exam

IRVINE, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that the Company's CEO will participate at the 2022 BTIG Biotechnology Conference being held in person in New York City on Monday, August 8th and Tuesday August 9th, 2022. The Company's CEO will also be available for in-person one-on-one meetings at the conference.

Biomerica to Participate at BTIG Biotech Conference

- Attaining CE Mark is a major step toward commercialization –

Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™

Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection

Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population

IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced its fiscal third quarter and nine month results ended February 28, 2022.

Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021

IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced positive topline results from the endpoint clinical trial of its InFoods® IBS diagnostic-guided therapy (DGT), with the trial showing statistically significant improvements in multiple endpoints in the Intent-to-Treat population. The InFoods® DGT is the first of its kind therapy for Irritable Bowel Syndrome (IBS) that uses a simple blood test designed to identify patient-specific foods that when removed from the diet may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The InFoods® IBS DGT works by identifying above normal immunoreactivity to specific foods in patients. A food identified as positive is simply removed from the diet for the patient to feel better.

Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

IRVINE, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its second quarter fiscal 2022 financial results.

News for Biomerica Stock (BMRA)